These findings suggest an association between the activation of IDO1 and JAK2/STAT3 pathways and the progression of hepatic fibrosis, indicating the potential utility of DSS as a complementary agent for the treatment and prevention of hepatic fibrosis [114]. The gene discussed is STAT3; the disease is Hepatic fibrosis.